Clinical trial
Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or…
NCT00470379 · Mayo Clinic, Other · Completed
Key facts
| NCT number | NCT00470379 |
|---|---|
| Title | Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery |
| Official title | Transcutaneous (Topical) Peptide Immunization With NY-ESO-1b (SLLMWITQC) Peptide Using Resiquimod as an Immune Adjuvant: A Pilot Study |
| Lead sponsor | Mayo Clinic, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Early Phase 1 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Drug |
| Interventions | resiquimod |
| Enrollment | 30 |
| Start date | Apr 1, 2006 |
| Primary completion | Oct 1, 2011 |
| Completion | Oct 1, 2011 |
| First posted | May 7, 2007 |
| Last update posted | Oct 31, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: